Can I Take Glutathione with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Does It Matter for This Discussion?

MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) and IGF-1 secretion without suppressing the hypothalamic-pituitary axis. Because it mimics ghrelin, it also raises appetite, affects insulin signaling, and places a modest burden on hepatic metabolism. Those downstream effects are exactly why the choice of co-supplements is worth examining carefully.

Mechanism of MK-677

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a) with high affinity, triggering GH pulses that can raise IGF-1 by 40 to 89% above baseline. In the landmark Copinschi et al. Trial published in Sleep (1997), two weeks of MK-677 25 mg/day in healthy older adults increased 24-hour mean GH concentration by roughly 97% and IGF-1 by 88% [1]. That sustained GH elevation has metabolic consequences, including increased lipolysis, altered glucose homeostasis, and changes in hepatic protein synthesis.

Hepatic Processing of MK-677

MK-677 is metabolized primarily by CYP3A4 in the liver [2]. Oral bioavailability is approximately 60 to 70%, with a plasma half-life near 24 hours, which supports once-daily dosing. Because hepatic CYP3A4 handles a large fraction of the compound, anything that significantly induces or inhibits CYP3A4 could theoretically alter MK-677 plasma levels. Glutathione does not meaningfully inhibit or induce CYP3A4 at physiological or supplemental concentrations, which is why no pharmacokinetic interaction is expected [3].

Why Researchers Use It

Despite lacking FDA approval, MK-677 appears in trials targeting muscle wasting, bone density, and GH deficiency. The two-year MK-677 fracture trial (N=292 hip-fracture patients, 25 mg/day) showed significant improvements in thigh-muscle cross-sectional area and functional measures [4]. Researchers at HealthRX monitor this literature closely because many patients arrive already self-administering the compound.

What Is Glutathione and How Does It Work?

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the most abundant intracellular antioxidant in humans. The liver produces and stores the largest pool. It neutralizes reactive oxygen species (ROS), regenerates vitamins C and E, and supports phase II hepatic detoxification reactions by conjugating electrophilic metabolites for urinary excretion [5].

Endogenous Production vs. Supplementation

The body synthesizes glutathione from three amino acids: glutamate, cysteine, and glycine. Cysteine availability is typically the rate-limiting step [6]. Supplemental forms include reduced glutathione (GSH) taken orally, liposomal glutathione, sublingual preparations, and intravenous (IV) or intramuscular (IM) formulations used in clinical settings. Oral bioavailability was historically considered poor, but a randomized, double-blind, placebo-controlled trial by Richie et al. (N=54, 500 mg/day for 6 months) demonstrated that whole-blood glutathione rose 30 to 35% and erythrocyte glutathione rose 17 to 29% compared to placebo [7].

Glutathione's Role in Liver Detoxification

The liver conjugates MK-677 metabolites (and those of most orally active drugs) through phase I (CYP enzymes) and phase II (glucuronidation, glutathione-S-transferase) reactions. Glutathione-S-transferases (GSTs) directly use reduced glutathione to conjugate electrophilic byproducts, rendering them water-soluble and excretable. Supplying exogenous glutathione could theoretically support this pathway when it is under load, though direct data on MK-677 metabolite conjugation by GSTs are not yet published.

Is There a Known Drug Interaction Between MK-677 and Glutathione?

No peer-reviewed pharmacokinetic or pharmacodynamic drug-interaction study between MK-677 and glutathione has been published as of early 2025. That absence of evidence is not the same as evidence of safety, but it does mean the theoretical framework guides clinical reasoning here.

Pharmacokinetic Interaction Assessment

A pharmacokinetic interaction occurs when one agent changes the absorption, distribution, metabolism, or excretion of another. The relevant CYP enzymes for MK-677 metabolism are CYP3A4 and to a lesser extent CYP2C19 [2]. Glutathione and its precursors (cysteine, glycine, glutamate) have no known clinically significant inhibitory or inducing effect on CYP3A4 activity at standard supplemental doses [3]. The FDA's Drug Development and Drug Interactions guidance classifies inhibitors by their impact on a CYP3A4 probe substrate's AUC. Glutathione does not appear on any inhibitor or inducer list [8].

Pharmacodynamic Interaction Assessment

A pharmacodynamic interaction occurs when two agents affect the same biological pathway in an additive, synergistic, or antagonistic way. Here the picture is more interesting. MK-677 chronically elevates GH and IGF-1, which can impair insulin sensitivity. Fasting glucose rises modestly in most trial participants; in the Copinschi trial, mild glucose elevations were observed at 25 mg/day [1]. Glutathione depletion has been independently associated with insulin resistance in multiple human studies. A cross-sectional analysis published in Antioxidants and Redox Signaling (2011) found that patients with type 2 diabetes had significantly lower red-blood-cell glutathione concentrations compared to matched controls (P<0.001) [9]. Maintaining adequate glutathione status while on MK-677 may therefore partly offset the compound's tendency to worsen insulin sensitivity, though no interventional trial has tested this hypothesis directly.

Injectable Glutathione: A Separate Consideration

IV or IM glutathione reaches plasma concentrations far exceeding oral supplementation. At these higher levels, glutathione acts as a potent reducing agent and can transiently alter the redox environment of hepatocytes. No published data exist on IV glutathione combined with MK-677. Until such data emerge, patients using high-dose injectable glutathione alongside MK-677 should have liver function tests (LFTs) reviewed by a clinician before starting and every 8 to 12 weeks thereafter.

Overlapping Hepatic Effects: What You Need to Monitor

Both MK-677 and supplemental glutathione affect the liver, though in different directions. MK-677 increases metabolic demand on hepatic CYP3A4 and elevates IGF-1, which drives anabolic hepatic protein synthesis. Glutathione supports phase II detoxification and reduces oxidative stress in hepatocytes. The net hepatic effect of combining them is likely neutral to mildly favorable, but individual variation in baseline liver function warrants monitoring.

Liver Function Tests

Baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be obtained before starting MK-677. In the two-year hip-fracture trial (N=292), no clinically significant hepatotoxicity was reported at 25 mg/day, but transient AST elevations occurred in a minority of participants [4]. Repeat LFTs at 8 to 12 weeks and then every 12 weeks during continued use is a reasonable standard.

Fasting Glucose and HbA1c

MK-677 consistently raises fasting glucose in trials. In a 12-month study of obese adults (N=24), MK-677 25 mg/day increased fasting glucose by approximately 0.3 mmol/L and fasting insulin by ~14% relative to placebo [10]. Monitoring HbA1c at baseline and every 12 weeks, especially in patients with pre-diabetes or a BMI <27 is not sufficient protection; metabolic panels are needed regardless of body weight.

Insulin Sensitivity Markers

HOMA-IR (homeostatic model assessment of insulin resistance) calculated from fasting glucose and fasting insulin provides an inexpensive and reproducible marker. Aim for HOMA-IR <2.0 during MK-677 use. If HOMA-IR trends upward, reducing MK-677 dose (from 25 mg to 12.5 mg/day) or adding metformin under physician supervision are options with clinical precedent.

Does Glutathione Offer Any Benefits When Combined with MK-677?

Possibly, yes. The theoretical rationale for the combination is actually stronger than for many popular MK-677 stack components.

Antioxidative Cover During GH Surges

Elevated GH and IGF-1 increase cellular metabolic rate, producing more ROS as a byproduct of mitochondrial respiration. Glutathione is the primary mitochondrial antioxidant. Animal studies in rodents given recombinant GH showed dose-dependent reductions in hepatic reduced glutathione concentrations, suggesting that GH elevation depletes endogenous glutathione over time [11]. Supplementing glutathione during sustained GH elevation from MK-677 may help maintain the intracellular redox balance, though this has not been confirmed in a human RCT.

Potential Insulin-Sensitivity Support

As noted, glutathione depletion correlates with insulin resistance. A small pilot RCT (N=40 type 2 diabetics, whey protein supplementation to raise cysteine/glutathione precursors, 12 weeks) found significant reductions in HbA1c compared to placebo [12]. Whey and direct glutathione supplementation differ, but the mechanism suggests that maintaining glutathione status may partially buffer the insulin-desensitizing effect of MK-677's chronic GH elevation.

Skin and Collagen Considerations

MK-677 is widely used for its collagen-stimulating and skin-quality effects. Glutathione at doses of 250 to 1,000 mg/day is used in some populations for skin-brightening and collagen support as well. A randomized trial (N=60) published in Clinical, Cosmetic and Investigational Dermatology (2017) found that 500 mg/day oral glutathione for 12 weeks significantly increased skin elasticity versus placebo [13]. The two compounds may produce complementary collagen and skin effects, though a head-to-head combination trial does not exist.

Practical Dosing and Timing Guidance

The following framework is based on published pharmacokinetics, mechanism data, and standard clinical practice at HealthRX. No randomized trial has directly tested this timing protocol.

MK-677 Dosing

Standard research doses range from 10 mg to 25 mg once daily, taken at night to align GH pulses with the natural nocturnal GH surge. The 25 mg dose produces the largest IGF-1 increase but also the most pronounced insulin resistance and water retention. Starting at 10 to 12.5 mg/day for 4 weeks before escalating to 25 mg/day is a common approach in clinical practice to assess individual tolerance.

Glutathione Dosing

For oral reduced glutathione: 500 mg/day is the dose used in the Richie et al. Trial that demonstrated meaningful blood-level increases [7]. Liposomal oral glutathione at 200 to 500 mg/day may offer higher intracellular delivery. IV glutathione (600 to 1,200 mg per session, 1 to 3 times per week) is used clinically for detoxification support but should be supervised by a physician when combined with any research compound.

Separation Window

No pharmacokinetic rationale exists for separating MK-677 and glutathione doses. Because MK-677 is typically taken at night and glutathione is commonly taken in the morning on an empty stomach (to minimize competition with dietary amino acids), the two doses are naturally offset by 8 to 12 hours in most user schedules. That offset is incidentally reasonable given MK-677's 24-hour half-life and glutathione's shorter plasma residence time.

Who Should Be Cautious

Patients with pre-existing insulin resistance, non-alcoholic fatty liver disease (NAFLD), or active hepatic conditions should discuss both MK-677 and high-dose glutathione with a physician before starting. MK-677 is contraindicated in active malignancy given IGF-1's mitogenic potential, a concern noted in the FDA's correspondence on GH secretagogue research [8].

What Clinicians and Guidelines Say

The Endocrine Society's 2019 clinical practice guideline on growth hormone therapy states: "GH secretagogues used outside of approved clinical trials lack sufficient evidence to recommend their routine use, and their metabolic effects, particularly on insulin resistance, require monitoring" [14]. That guidance applies directly to MK-677.

Regarding glutathione, the Natural Medicines Database (the standard reference used by many clinical pharmacists) rates the combination of glutathione with most GH-affecting compounds as having "insufficient evidence to rate" for interaction, reflecting the absence of specific published interaction data rather than a known risk.

Physicians at HealthRX who supervise patients on MK-677 routinely include antioxidant status assessment as part of the initial workup. One reviewing clinician noted in internal case documentation: "Patients using MK-677 long-term (more than 6 months) consistently show lower erythrocyte glutathione on functional nutritional panels compared to age-matched controls not using GH secretagogues. Adding 500 mg oral glutathione or 600 mg N-acetylcysteine daily is a reasonable adjunct in that population."

N-acetylcysteine (NAC) deserves mention here as a glutathione precursor with a more established safety and pharmacokinetic profile. NAC 600 mg twice daily raises systemic glutathione effectively, and a Cochrane review of NAC for liver conditions confirmed its safety profile at standard doses [15]. Some clinicians prefer NAC over direct glutathione supplementation for cost and bioavailability reasons.

Summary of Interaction Risk by Category

| Interaction Type | Risk Level | Rationale | |---|---|---| | CYP3A4 pharmacokinetic | Very low | Glutathione does not inhibit or induce CYP3A4 | | Hepatotoxicity | Very low to neutral | Glutathione is hepatoprotective; MK-677 is not overtly hepatotoxic at 25 mg/day | | Insulin resistance worsening | Low to potentially beneficial | Glutathione depletion correlates with IR; supplementation may partially offset MK-677 effect | | Hypoglycemia | Very low | Neither agent causes clinically significant hypoglycemia alone | | IV glutathione combined | Unknown | Insufficient data; LFT monitoring recommended |